Reply to the letter regarding the article ‘Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction’
2024

Response to Comments on SGLT2 Inhibitors and Muscle Health

Commentary Evidence: moderate

Author Information

Author(s): Wood Nathanael, Witte Klaus K., Bowen T. Scott

Primary Institution: University of Leeds

Conclusion

The study provides important insights into the effects of SGLT2 inhibitors on skeletal muscle pathology in patients with heart failure and reduced ejection fraction.

Supporting Evidence

  • The study highlights the need for further research on SGLT2 inhibitors and muscle health.
  • Sample collection coincided with the approval of SGLT2 inhibitors, allowing for relevant comparisons.
  • Standard practices were followed to minimize bias in the study.

Takeaway

The researchers are saying that SGLT2 inhibitors might help with muscle problems in heart failure patients, but more research is needed to understand how they work.

Methodology

The study involved longitudinal sample collection and comparisons between treated and untreated groups, along with controlled experiments in a mouse model.

Potential Biases

The researchers ensured no bias by keeping samples separate from clinical data until analysis.

Limitations

The study did not have definitive diagnoses for all patients' heart failure causes and lacked comprehensive muscle assessments.

Participant Demographics

Participants included older individuals with heart failure and reduced ejection fraction.

Digital Object Identifier (DOI)

10.1002/ejhf.3442

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication